Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 14, 2022; 28(30): 4182-4200
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4182
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4182
Figure 1 Patient flow diagram.
DAA: Direct-acting antivirals; dLC: Decompensated liver cirrhosis; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; IBT: Interferon-based treatment; HIV: Human immunodeficiency virus; LT: Liver transplantation.
- Citation: Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Jang JW, Ki M, Choi HY, Baik D, Jeong SH. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. World J Gastroenterol 2022; 28(30): 4182-4200
- URL: https://www.wjgnet.com/1007-9327/full/v28/i30/4182.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i30.4182